Generation Bio Co. (NASDAQ:GBIO) Short Interest Update

Generation Bio Co. (NASDAQ:GBIO) saw a large decrease in short interest in November. As of November 15th, there was short interest totalling 1,480,000 shares, a decrease of 10.8% from the October 31st total of 1,660,000 shares. Based on an average trading volume of 129,800 shares, the days-to-cover ratio is presently 11.4 days. Currently, 3.2% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of research firms have weighed in on GBIO. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Generation Bio in a research report on Wednesday, October 23rd. Wedbush reiterated an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a research report on Thursday, November 7th.

Generation Bio Trading Down 3.5 %

Shares of GBIO stock traded down $0.05 on Tuesday, reaching $1.37. The company’s stock had a trading volume of 403,896 shares, compared to its average volume of 182,021. The stock’s fifty day simple moving average is $2.09 and its 200-day simple moving average is $2.55. Generation Bio has a 1 year low of $1.24 and a 1 year high of $4.65.

Institutional Trading of Generation Bio

Several hedge funds have recently made changes to their positions in GBIO. Rhumbline Advisers boosted its stake in Generation Bio by 7.4% during the second quarter. Rhumbline Advisers now owns 78,903 shares of the company’s stock worth $222,000 after buying an additional 5,430 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Generation Bio by 2.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock valued at $1,046,000 after purchasing an additional 8,692 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in Generation Bio by 91.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock worth $54,000 after purchasing an additional 9,075 shares during the period. State Street Corp lifted its stake in Generation Bio by 1.2% in the third quarter. State Street Corp now owns 992,188 shares of the company’s stock worth $2,451,000 after purchasing an additional 11,669 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Generation Bio by 8.7% during the second quarter. The Manufacturers Life Insurance Company now owns 164,573 shares of the company’s stock valued at $464,000 after buying an additional 13,104 shares during the last quarter. 95.22% of the stock is currently owned by hedge funds and other institutional investors.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.